Neurocognitive outcomes of children with osteosarcoma treated with methotrexate

Pediatr Int. 2023 Jan;65(1):e15487. doi: 10.1111/ped.15487.

Authors

Haruko Shima¹, Satomi Sato², Tetsuya Takimoto³, Michiko Sakai¹, Noriko Hashida¹, Kyohei Isshiki¹, Hiroyuki Shimada¹

Affiliations

¹ Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
² Division of Health and Behavioral Sciences, St. Luke's International University, Tokyo, Japan.
³ Department of Data Management, National Center for Child Health and Development, Tokyo, Japan.

PMID: 36799122
DOI: 10.1111/ped.15487

No abstract available

Keywords: children; late effects; methotrexate; neurocognitive outcomes; osteosarcoma.

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Bone Neoplasms* / drug therapy
Child
Humans
Methotrexate / therapeutic use
Osteosarcoma* / complications
Osteosarcoma* / drug therapy

Substances

Methotrexate
Antimetabolites, Antineoplastic

Grants and funding

26780410/MEXT Grant-in-Aid for Scientific Research